Press release
Biobetters Market to Exceed CAGR 8% by 2029
Increasing usage of therapeutically more effective drugs for the treatment of chronic diseases is expected to drive the growth of biobetters market. Higher efficacy and lower adverse effects are among the important factors that are expected to fuel the growth of the biobetters market over the forecast period. According to the latest research by the company, the global biobetters market is projected to account for a market value of around US$ 99,000.0 Mn by the end of 2029. The report also projects a significant growth potential for the biobetters market throughout the forecast period.View Full Report @ https://www.persistencemarketresearch.com/market-research/biobetters-market.asp
Better Therapeutic Outcome at Lower Costs
Lower cost of treating various chronic diseases with the usage of biobetters is one of the prominent factors contributing to the substantial growth of the biobetters market. Biobetters are more effective and longer-acting medicines as compared to biosimilars, which are their reference biologic products. Although biosimilars are 20 to 30% cheaper as compared to biobetters, superior efficacy and lesser dosage frequency makes biobetters a preferred treatment option.
Moreover, the treatment cost of each cycle using biobetters is relatively lower than that of biologics. For example, Neulasta, a biobetter of Neupogen, costs around US$ 3,400 – 4,000 for each treatment cycle, whereas Neupogen cost around US$ 6,000 at the inception. Although the cost of Neulasta increased considerably, it made only a little difference due to its increased patient compliance and efficacy. However, the market share of Neupogen and its biosimilars remains significantly low, when compared to Neulasta. The superiority of biobetters in terms of pricing, dosage, efficacy, etc. makes them among the most preferred treatment options among patients as well as healthcare professionals.
Get Sample Copy of This Report @ https://www.persistencemarketresearch.com/samples/21151
Various pharmaceutical and biopharmaceutical companies are seeking approval for their respective biobetters for the treatment various diseases. For example, on May 7, 2019, Roche received approval for its Kadcyla drug for the adjuvant treatment of HER2-positive early breast cancer in patients who are affected by residual invasive disease after undergoing neoadjuvant taxane-trastuzumab-based treatment. Kadcyla was earlier approved for the treatment of HER2-positive metastatic breast cancer. In March 2017, Roche received FDA approval for its drug named Ocrevus (ocrelizumab) for the treatment of the relapsing form of multiple sclerosis.
Pharma and Biopharma Companies Investing in R&D
In terms of revenue, the insulin biobetters segment by drug class in the biobetters market is expected to be a prominent segment over the forecast period. By indication, the biobetters market is expected to be dominated by diabetes over the forecast period due to the higher prevalence of the disease. By route of administration, the subcutaneous segment of the biobetters market is expected to generate significant revenue during the forecast period due to superior drug delivery as compared to intravenous. By distribution channel, the biobetters market is expected to be dominated by the retail pharmacies segment due to higher patient footfall.
Ask Querie to Industry Expert @ https://www.persistencemarketresearch.com/ask-an-expert/21151
North America is expected to be a prominent biobetters market through 2029. Biobetters are approved through the biologics approval pathway as new molecules and hence, they have 10 to 12 years of marketing exclusivity in regions such as North America and Europe, which allows pharmaceutical and biopharmaceutical companies to invest in R&D as it provides assurance to the manufacturers. The manufacturers of originator biologics tend to develop biobetters of their own product, which allows them to maintain/increase their market share due to the superior qualities of biobetters even after the patent expiry of originator biologics. For example, Amgen Inc., a manufacturer of Neupogen, launched Aranesp, a drug used for the treatment of anaemia in patients suffering from chronic kidney diseases as well as chemotherapy/radiation-induced myelosuppression in cancer patients.
The report also profiles some of the key companies operating in the biobetters market such as F. Hoffmann-La Roche AG, Amgen Inc., Sanofi SA, Merck & Co. Inc., Porton Biopharma Limited, SERVIER, Novo Nordisk A/S, Eli Lily and Company, CSL Behring GmbH, Biogen Inc., and Teva Pharmaceutical Industries Ltd., among others.
Contact us:
305 Broadway, 7th Floor
New York City, NY 10007
United States
Ph.no. +1-646-568-7751
E-mail id- sales@persistencemarketresearch.com
Website: www.persistencemarketresearch.com
About Us
Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.
To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.
Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMR’s collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Biobetters Market to Exceed CAGR 8% by 2029 here
News-ID: 1855532 • Views: …
More Releases from Persistence Market Research

Silicon Carbide Fibers Market Set for Explosive Growth to 2031 Opportunities, Tr …
Silicon carbide fibers are gaining significant momentum in advanced material applications due to their exceptional properties, including high strength, lightweight structure, corrosion resistance, and outstanding thermal stability. These fibers are primarily used in industries that demand superior performance in extreme conditions, such as aerospace, defense, energy, and automotive.
According to persistence market research The silicon carbide fibers market is estimated to increase from US$0.867 Bn in 2024 to US$5.1 Bn by…

U.S. Ion Exchange Resin Market to Reach US$568.2 Mn by 2031
Ion exchange resins are critical materials in water treatment, chemical processing, power generation, pharmaceuticals, and food and beverage industries. These resins play a vital role in purifying water, separating ions, and facilitating catalytic processes. With rising concerns over environmental sustainability, industrial water requirements, and advancements in resin technologies, the demand for ion exchange resins has significantly increased in the United States.
According to persistence market research the U.S. ion exchange resin…

Dermatology Imaging Market is Anticipated to Hold a Value worth US$ 6.1 Billion …
The dermatology imaging market plays a crucial role in enhancing the diagnosis, treatment, and monitoring of skin-related disorders. Dermatology imaging devices, including dermatoscopes, confocal microscopes, and multispectral imaging systems, provide high-resolution images that enable early detection of skin cancers, psoriasis, acne, and other dermatological conditions.
Request a Sample: https://www.persistencemarketresearch.com/samples/35200
According to the latest study by Persistence Market Research, the global dermatology imaging market size is anticipated to reach a value of…

Neonatal Phototherapy Devices Market Size to Reach over USD 147.9 Million by 203 …
The neonatal phototherapy devices market plays a crucial role in the treatment of neonatal jaundice, a common condition in newborns characterized by elevated bilirubin levels. These devices use controlled light therapy to reduce bilirubin in infants' blood, preventing severe complications such as kernicterus and brain damage. According to the latest study by Persistence Market Research, the global neonatal phototherapy devices market size is anticipated to value at US$ 110.4 Mn…
More Releases for Neupogen
Neupogen Market Expansion Fueled by Cancer Supportive Care and Neutropenia Treat …
The qualitative latest Research report (2025-2032) on the Neupogen Market by Coherent Market Insights Provides a deep dive into key market trends, drivers, challenges, and the competitive landscape. It analyzes market size, revenue, production, and CAGR using validated methodologies to ensure precision. The report highlights tech innovation, pricing trends, consumer behavior, and investment potential - empowering businesses to make informed, strategic moves.
Request a Sample Copy: https://www.coherentmarketinsights.com/insight/request-sample/8115
Focused on growth and future…
Neupogen Market Set to Witness Significant Growth from 2025 to 2032, Highlightin …
The Neupogen Market 2025 Forecast to 2032" research provides accurate economic, global, and country-level predictions and analyses. It provides a comprehensive perspective of the competitive market as well as an in-depth supply chain analysis to assist businesses in identifying major changes in industry practices. The market report also examines the current state of the Neupogen industry, as well as predicted future growth, technological advancements, investment prospects, market economics, and financial…
Neupogen Market Surging as Biosimilars Take Over and Supportive Cancer Care Expa …
The Global Neupogen Market is expected to decline from USD 89.2 Mn in 2025 to USD 30.5 Mn by 2032, with a negative CAGR of -14.2% over the forecast period.
The latest Neupogen Market research report offers crucial insights into how the industry is evolving, highlighting key drivers of growth and the main revenue streams expected between 2025 and 2032. It analyzes market size, revenue, production, and CAGR using validated…
Comprehensive Neupogen (filgrastim) Market Insights: Forecasting Size, Growth, a …
How Are the key drivers contributing to the expansion of the neupogen (filgrastim) market?
The advancement of the neupogen (filgrastim) market is anticipated due to an escalating occurrence of diverse diseases. Diseases refer to irregularities in bodily functions or structures that manifest particular symptoms and commonly impact specific areas, generally induced by environmental factors, lifestyle choices, infections, or genetics. The escalating prevalence of diseases is propelled by elements like an aging…
Neupogen (filgrastim) Market Outlook 2025-2034: Key Trends, Growth Drivers, and …
How Big Is the Neupogen (filgrastim) Market Expected to Be, and What Will Its Growth Rate Be?
In the recent past, the market size of neupogen (filgrastim) has seen a significant surge. The sector is expected to boost from $1,330.69 million in 2024, reaching up to $1,404.70 billion in 2025 with a compound annual growth rate (CAGR) of 5.6%. Factors such as a surge in cancer cases, increased understanding of chemotherapy-induced…
Biosimilar Competition Market 2019 |Is Heating-up! Have You Mapped Your Competit …
Biosimilar approvals have increased steeply in the recent years. Europe leads in terms of biosimilar approvals. However, the U.S. has also shown significant growth in terms of biosimilar approvals. Sandoz’s Zarxio, a biosimilar to Amgen’s bone marrow stimulant Neupogen (filgrastim) — was the first biosimilar approved in the U.S., followed by three approvals in 2016. The number has increased to nine in 2017 and hit a record number of 16…